Counselors in Assonet, MA Accepting Medicare
5 Counselors found. Showing 1 - 5
 Mr. Thomas David Loftus, MS, LMHC Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 22 Joaquin Ave, Assonet, MA 02702 Phone: 508-644-5307 |
 Jillian H Pavadore, MA, LMHC Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 18 Central Ave, Assonet, MA 02702 Phone: 774-306-7114 |
Stavroula Kulpa, M.ED.,C.A.G.S, L.M.H Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 9 Jethol Dr, Assonet, MA 02702 Phone: 508-306-0560 |
Brian C Gamboa Counselor - Mental Health Medicare: Medicare Enrolled Practice Location: 3 Ashlawn Rd, Assonet, MA 02702 Phone: 508-933-5205 Fax: 877-308-2202 |
Heath Travis Kulpa Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 9 Jethol Dr, Assonet, MA 02702 Phone: 508-965-8359 |
News Archive
Longer looks: Falling teen birth rate; the right to pain relief; limiting access to Sovaldi
An infectious disease doctor at Tulane University, [MarkAlain] Dery treats people living with HIV in New Orleans and Baton Rouge, the two largest cities in the southern state of Louisiana, which itself has the fourth-highest rate of HIV in the United States, just behind New York, Florida and Maryland.
Pharmasset, Bristol-Myers Squibb initiate PSI-7977 plus BMS-790052 combination Phase 2a trial in HCV
Pharmasset, Inc. announced today the initiation of a Phase 2a trial investigating the combination of Pharmasset's PSI-7977, a nucleotide polymerase inhibitor, and BMS-790052, Bristol-Myers Squibb Company's NS5A replication complex inhibitor, for the treatment of chronic hepatitis C.
Intestinal worms have influence on allergy and asthma risk in humans
While young people with parasite worms currently have four times higher risk for developing allergies and asthma than others. Their parents are generally unaffected.
Synergy reports positive results from plecanatide Phase IIa clinical trial for chronic constipation
Synergy Pharmaceuticals, Inc., a developer of new drugs to treat gastrointestinal disorders and diseases, announced today positive results in a Phase IIa clinical trial of plecanatide (SP-304) in patients with chronic constipation. Oral plecanatide given once daily, over 14 consecutive days, at doses of 0.3, 1.0, 3.0 and 9.0 mg gave improved bowel function in patients with chronic constipation.
MED1 plays a central role in mediating tamoxifen resistance in breast cancer
A University of Cincinnati (UC) cancer biology team reports breakthrough findings about specific cellular mechanisms that may help overcome endocrine (hormone) therapy-resistance in patients with estrogen-positive breast cancers, combating a widespread problem in effective medical management of the disease.
› Verified 8 days ago